false
Hamburger Menu
Catalog
JTO Clinical and Research Reports, May 2022, Volum ...
JTO Clinical and Research Reports, May 2022, Volume 3, Issue 5 (CRR052022)
Journal | English | 2022
Create Account
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
Table of Contents
Original Articles:
Real-World Perspectives From Surgeons and Oncologists on Resectability Definition and Multidisciplinary Team Discussion of Stage III NSCLC in People’s Republic of China, Hong Kong, and Macau: A Physician Survey
Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society
Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With
BRAF
-Mutated Advanced NSCLC
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors
Case Reports
De Novo
KRAS
G12C–Mutant SCLC: A Case Report
Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report
TP53
Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
Brief Reports
Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
Review Articles
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice
The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review
Implementing Lung Cancer Screening in Europe: Taking a Systems Approach
About JTO Clinical and Research Reports
JTO Clinical and Research Reports
is the official open access journal of the
International Association for the Study of Lung Cancer
. It aims to complement the
Journal of Thoracic Oncology
by offering authors a gold open access publication option and publishing the following article types in particular:
Phase I trials
Well performed single-arm phase II trials
Subset analyses of published trials
Impactful retrospective Studies
Database analysis
Large institutional series
High-quality case reports
Region-specific clinical trials
Subspecialty thoracic oncology studies
Selected high-quality meeting reports
As an open access journal with no subscription charges,
JTO CRR
requires authors to pay a
fee
to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.
×
JTO Clinical and Research Reports, May 2022, Volume 3, Issue 5 (CRR052022) Course List
Login
User Login
Continue with Google
OR
Email
Password
Logging In…
Create Account
Forgot Password
×
Please select your language
1
English